Literature DB >> 9325334

Epidermal growth factor modulates tyrosine phosphorylation of p130Cas. Involvement of phosphatidylinositol 3'-kinase and actin cytoskeleton.

M Ojaniemi1, K Vuori.   

Abstract

Epidermal growth factor (EGF) treatment of Rat-1 cells expressing human EGF receptor results in the modification of the tyrosine phosphorylation of the p130 Crk-associated substrate (Cas), a novel signaling molecule residing in focal adhesions. At low, mitogenic concentrations (<10 ng/ml), EGF treatment induced a rapid and transient tyrosine phosphorylation of Cas and promoted the formation of a Cas-adapter protein Crk complex in intact cells. The increase in tyrosine phosphorylation of Cas paralleled an increase in the cellular content of actin stress fibers and occurred via a pathway that depended on the integrity of the cytoskeleton. Further, phosphatidylinositol 3'-kinase activity was found to be required for the EGF-stimulated Cas phosphorylation and actin polymerization. At high concentrations (>30 ng/ml), EGF treatment resulted in the tyrosine dephosphorylation of Cas in a time-dependent manner with a concomitant decrease in the length and number of actin stress fibers. Thus, Cas exhibits an unusual bell-shaped dose-response curve in response to EGF stimulation. These results demonstrate a novel signaling role for EGF in inducing changes in tyrosine phosphorylation of Cas and Cas-Crk complex formation and suggest that Cas could be a signaling component in EGF-mediated signal transduction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325334     DOI: 10.1074/jbc.272.41.25993

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  CMS: an adapter molecule involved in cytoskeletal rearrangements.

Authors:  K H Kirsch; M M Georgescu; S Ishimaru; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  The actin-driven movement and formation of acetylcholine receptor clusters.

Authors:  Z Dai; X Luo; H Xie; H B Peng
Journal:  J Cell Biol       Date:  2000-09-18       Impact factor: 10.539

3.  Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers.

Authors:  S K Muthuswamy; M Gilman; J S Brugge
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  Cas mediates transcriptional activation of the serum response element by Src.

Authors:  Y Hakak; G S Martin
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

6.  Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton.

Authors:  Michael S Guerrero; J Thomas Parsons; Amy H Bouton
Journal:  Genes Cancer       Date:  2012-05

7.  P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading.

Authors:  Paola Di Stefano; Sara Cabodi; Elisabetta Boeri Erba; Valentina Margaria; Elena Bergatto; Maria Gabriella Giuffrida; Lorenzo Silengo; Guido Tarone; Emilia Turco; Paola Defilippi
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

8.  AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern.

Authors:  Anthony Makkinje; Richard I Near; Giuseppe Infusini; Pierre Vanden Borre; Alexander Bloom; Dongpo Cai; Catherine E Costello; Adam Lerner
Journal:  Cell Signal       Date:  2009-05-18       Impact factor: 4.315

9.  Netrin-1 attracts axons through FAK-dependent mechanotransduction.

Authors:  Simon W Moore; Xian Zhang; Christopher D Lynch; Michael P Sheetz
Journal:  J Neurosci       Date:  2012-08-22       Impact factor: 6.167

10.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.